Alzheon hits another dead end funding its Alzheimer's program, pulls second IPO attempt

If at first you don’t succeed… maybe it wasn’t such a good idea.

Alzheon has learned that the hard way as it withdraws its IPO for a second time, despite drastically downsizing the offering and adjusting its goal from a Phase III pivotal study to a Phase IIb for its lead drug.